AlphaCentric Advisors
NTLA icon

AlphaCentric Advisors’s Intellia Therapeutics NTLA Stock Holding History

AlphaCentric Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$148K Buy
12,276
+604
+5% +$7.55K 0.13% 188
2026
Q2 		$197K Buy
11,672
+166
+1% +$2.32K 0.17% 161
2026
Q1 		$148K Buy
11,506
+626
+6% +$7.97K 0.15% 171
2025
Q4 		$97.8K Buy
+10,880
New +$150K 0.1% 223

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Contrarius Group Holdings
Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

AlphaCentric Advisors's NTLA Position: Q3 2026 in Review

AlphaCentric Advisors increased its Intellia Therapeutics (NTLA) stake by 5.2% in Q3 2026, buying an estimated $7.55K and bringing the position to 12,276 shares worth $148K. The position accounts for 0.13% of the portfolio, ranked #188.

AlphaCentric Advisors first reported a position in NTLA in Q4 2025 and has held it in 4 quarters since. The position peaked at $197K in Q2 2026. 156 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • AlphaCentric Advisors held 12,276 shares of Intellia Therapeutics worth $148K as of Q3 2026.
  • AlphaCentric Advisors bought 604 Intellia Therapeutics shares in Q3 2026, an estimated $7.55K.
  • Intellia Therapeutics made up 0.13% of AlphaCentric Advisors's portfolio in Q3 2026, its #188 holding.
  • AlphaCentric Advisors first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • AlphaCentric Advisors's Intellia Therapeutics position peaked at $197K in Q2 2026.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.